NCT03685682View on ClinicalTrials.gov

Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 25, 2018

Primary Completion Date

September 5, 2019

Study Completion Date

September 5, 2019

Conditions
Varicella Zoster Vaccine
Interventions
BIOLOGICAL

recombinant subunit Herpes zoster vaccine

Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months

Trial Locations (1)

M5G2N2

University Health Network, Toronto General Hospital, Multi-Organ Transplant, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03685682 - Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients | Biotech Hunter | Biotech Hunter